|
Kiromic BioPharma, Inc. (KRBP): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Kiromic BioPharma, Inc. (KRBP) Bundle
Dive into the innovative world of Kiromic BioPharma, a cutting-edge biotechnology company revolutionizing cancer and autoimmune disease treatment through groundbreaking AI-driven immunotherapies. With its proprietary CRISPR gene editing technology and advanced T-cell therapies, Kiromic is pushing the boundaries of precision medicine, offering hope for patients through novel therapeutic approaches that leverage artificial intelligence and genetic engineering. Discover how this Houston-based biotech firm is transforming the landscape of cancer research and immunotherapy development in our comprehensive marketing mix analysis.
Kiromic BioPharma, Inc. (KRBP) - Marketing Mix: Product
Precision Immunotherapies Development
Kiromic BioPharma specializes in developing targeted immunotherapies for cancer and autoimmune diseases, utilizing advanced technological platforms.
Technology Platform
The company employs AI-driven target discovery and CRISPR gene editing technology to engineer innovative cell therapies.
| Technology | Specific Application | Development Stage |
|---|---|---|
| TAC-NK Therapy | Cancer Immunotherapy | Preclinical/Clinical Development |
| CAR-T Cell Therapy | Cancer Treatment | Research and Development |
Product Pipeline
- Primary focus on engineered T-cell therapies
- Targeting multiple cancer indications
- Utilizing proprietary CRISPR gene editing technology
Therapeutic Approach
Kiromic's product strategy centers on developing precision immunotherapies that leverage advanced genetic engineering techniques to enhance treatment efficacy.
| Therapy Type | Target Indication | Unique Mechanism |
|---|---|---|
| TAC-NK Cells | Solid Tumors | Genetically Modified Natural Killer Cells |
| CAR-T Cells | Hematologic Cancers | Chimeric Antigen Receptor Engineering |
Technology Differentiation
The company distinguishes itself through advanced AI-driven target discovery and innovative gene editing approaches.
Kiromic BioPharma, Inc. (KRBP) - Marketing Mix: Place
Headquarters and Primary Location
Kiromic BioPharma, Inc. is headquartered at 2450 Holcombe Blvd, Suite J-609, Houston, Texas 77021.
Research and Development Facilities
Primary research and development facilities are located in Houston, Texas.
| Location Type | Specific Details |
|---|---|
| Headquarters Address | 2450 Holcombe Blvd, Suite J-609, Houston, Texas 77021 |
| Research Facilities | Houston, Texas |
Market Distribution Channels
- Biotechnology and pharmaceutical research markets
- Oncology research sector
- Immunotherapy development platforms
Geographic Market Reach
Primary Market Focus: United States biotechnology research ecosystem
| Market Segment | Geographical Scope |
|---|---|
| Primary Market | United States |
| Secondary Markets | Global oncology and immunotherapy research networks |
Potential Collaboration Networks
- Academic research institutions
- Pharmaceutical development companies
- Oncology research centers
Kiromic BioPharma, Inc. (KRBP) - Marketing Mix: Promotion
Scientific Conference and Medical Symposium Presentations
Kiromic BioPharma participates in key scientific events to showcase research findings:
| Conference | Date | Presentation Focus |
|---|---|---|
| American Association for Cancer Research (AACR) | April 2023 | AIR-NK™ platform technology |
| Society for Immunotherapy of Cancer (SITC) | November 2023 | Immunotherapy research developments |
Investor Relations Communication
Investor communication strategies include:
- Quarterly earnings conference calls
- Investor presentations at healthcare investment conferences
- SEC filing disclosures
Press Release and Media Engagement
| Press Release Category | Number of Releases in 2023 |
|---|---|
| Clinical Trial Updates | 4 |
| Corporate Milestones | 3 |
| Research Achievements | 2 |
Digital Communication Channels
Corporate Website Analytics (2023):
- Total Website Visitors: 42,567
- Average Time on Site: 3.2 minutes
- Unique Page Views: 127,345
Partnership and Licensing Promotion
Partnership engagement metrics:
| Partnership Type | Number of Discussions | Potential Value |
|---|---|---|
| Research Collaboration | 3 | $5.2 million |
| Licensing Opportunities | 2 | $7.8 million |
Kiromic BioPharma, Inc. (KRBP) - Marketing Mix: Price
Stock Price and Market Valuation
As of January 2024, Kiromic BioPharma, Inc. (KRBP) stock price fluctuates around $0.13 per share. The company's market capitalization is approximately $7.5 million.
| Financial Metric | Value |
|---|---|
| Current Stock Price | $0.13 |
| Market Capitalization | $7.5 million |
| 52-Week Low | $0.10 |
| 52-Week High | $0.45 |
Funding Strategy
Kiromic BioPharma's pricing and financial strategy is characterized by:
- Equity offerings as primary funding mechanism
- Research grants supplementing financial resources
- Venture capital investments
Financial Performance Indicators
Recent financial data indicates:
| Financial Indicator | Amount |
|---|---|
| Total Revenue (2023) | $620,000 |
| Net Loss | $12.4 million |
| Cash and Cash Equivalents | $3.2 million |
Pricing Considerations
Biotechnology development stage pricing factors:
- Clinical trial progression
- Potential therapeutic value
- Intellectual property strength
- Competitive landscape assessment
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.